degarelix Side Effects
Also known as: Firmagon
Analysis of 4,979 adverse event reports submitted to the FDA from 2007 to 2025.
Total Reports
4,979
Death-Related
576
11.6% of reports
Hospitalizations
1,629
32.7% of reports
Top Indication
Prostate Cancer
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 576 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 190 |
| DISEASE PROGRESSION | 97 |
| PROSTATE CANCER | 39 |
| MALIGNANT NEOPLASM PROGRESSION | 33 |
| PROSTATE CANCER METASTATIC | 28 |
| ASTHENIA | 23 |
| FATIGUE | 21 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 19 |
| PNEUMONIA | 19 |
| MYOCARDIAL INFARCTION | 17 |
| CARDIAC ARREST | 16 |
| DYSPNOEA | 16 |
| FALL | 16 |
| PAIN | 15 |
| ANAEMIA | 14 |
| DECREASED APPETITE | 14 |
| PROSTATIC SPECIFIC ANTIGEN INCREASED | 14 |
| OFF LABEL USE | 13 |
| PYREXIA | 12 |
| CEREBROVASCULAR ACCIDENT | 11 |
Reactions in Hospitalization Reports
Top reactions in 1,629 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| FATIGUE | 109 |
| FALL | 98 |
| PYREXIA | 93 |
| ASTHENIA | 69 |
| ANAEMIA | 62 |
| ACUTE KIDNEY INJURY | 57 |
| DYSPNOEA | 57 |
| INJECTION SITE PAIN | 56 |
| CEREBROVASCULAR ACCIDENT | 55 |
| DEHYDRATION | 55 |
| MALAISE | 55 |
| ABDOMINAL PAIN | 54 |
| PAIN | 54 |
| URINARY TRACT INFECTION | 53 |
| DEATH | 49 |
| DIZZINESS | 49 |
| DIARRHOEA | 48 |
| DECREASED APPETITE | 47 |
| INJECTION SITE ERYTHEMA | 47 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 44 |
Nearby — Related Medications
What the FAERS Data Reveals About degarelix Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 4,979 voluntary reports linked to degarelix and its brand equivalents (Firmagon), spanning 2007 through 2025. Of those, 576 (11.6%) listed death as an outcome and 1,629 (32.7%) involved hospitalization. The most common indication reported alongside adverse events was Prostate Cancer.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 1% were female and 99% male; age distribution skews toward 75+, with 1,199 reports in that bracket. The single most reported reaction is fatigue with 377 submissions, followed by injection site pain and hot flush.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.